Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe
Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Patricia Stewart
Authored Items
Sacituzumab plus Pembrolizumab Shows Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Patricia Stewart
TOP - May 2022 Vol 15, No 3
in
ASCO GU 2022 Highlights
Circulating Tumor DNA Profiling May Result in Improved Detection and Treatment of CNS Lymphoma
Patricia Stewart
TOP - May 2022 Vol 15, No 3
in
ASH 2021 Highlights
Pembrolizumab plus Chemotherapy Prolongs Survival in Patients with Triple-Negative Breast Cancer and PD-L1 Combined Positive Score ≥10
Patricia Stewart
TOP - March 2022 Vol 15, No 2
in
SABCS
Study Finds 1 in 6 Patients with Cancer Experience “Long-Haul” COVID-19
Patricia Stewart
TOP - March 2022 Vol 15, No 2
in
COVID-19 & Cancer
Adagrasib Shows Promising Activity in Patients with KRASᴳ¹²ᶜ-Mutated Metastatic Colorectal Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only
in
Colorectal Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only
in
Lung Cancer
Abiraterone Added to Androgen-Deprivation Therapy Significantly Improves Metastasis-Free Survival in Patients with High-Risk Prostate Cancer
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only
in
Prostate Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7
in
Lung Cancer
ALK-Targeted Therapy Appears Beneficial in Patients with Adult-Onset Neuroblastoma
Patricia Stewart
TOP - November 2021 Vol 14, No 7
in
Neuroblastoma
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5
in
Lung Cancer
Pathogenic Germline Variants Identified in Children with Neuroblastoma
Patricia Stewart
TOP - September 2021 Vol 14, No 5
in
Genetic Counseling
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5
in
Lung Cancer
Tebentafusp Improves Survival in Frontline Setting of Metastatic Uveal Melanoma
Patricia Stewart
TOP - September 2021 Vol 14, No 5
in
Melanoma
Addition of Copanlisib to Rituximab Improves Outcomes in Indolent NHL
Patricia Stewart
TOP - July 2021 Vol 14, No 4
in
Lymphoma
Experts Discuss the Current and Future Impact of COVID-19 Pandemic on Cancer Care
Patricia Stewart
TOP - July 2021 Vol 14, No 4
in
COVID-19
,
HOPA Highlights
Belzutifan: A New Approach to Treating Advanced Clear-Cell Renal-Cell Carcinoma
Patricia Stewart
TOP - May 2021 Vol 14, No 3
in
ASCO GU Cancer Highlights
Pembrolizumab plus Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
Patricia Stewart
TOP - May 2021 Vol 14, No 3
in
Breast Cancer
Abemaciclib plus Endocrine Therapy Offers Invasive Disease–Free Survival Benefit in Patients with High-Risk, HR-Positive, Early-Stage Breast Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3
in
Breast Cancer
Enfortumab Vedotin Prolongs Survival in Patients with Metastatic Bladder Cancer
Patricia Stewart
TOP - May 2021 Vol 14, No 3
in
ASCO GU Cancer Highlights
Momelotinib Yields Long-Term Survival Benefit in Intermediate- or High-Risk Myelofibrosis
Patricia Stewart
TOP - May 2021 Vol 14, No 3
in
Myelofibrosis
Promising Results Seen with Ruxolitinib as Second-Line Treatment for Chronic GVHD
Patricia Stewart
TOP - March 2021 Vol 14, No 2
in
ASH 2020 Highlights
Sotorasib Demonstrates Promising Antitumor Activity in Advanced NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Emerging Therapies
Xevinapant plus CRT Improves Survival in Patients with Locally Advanced HNSCC
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Emerging Therapies
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Lung Cancer
Consensus Builds for Aggressive Approach to High-Risk Smoldering Myeloma
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Hematologic Malignancies
New Regimens for Multiple Myeloma: Selecting the Right Treatment for the Right Patient
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Hematologic Malignancies
CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Patricia Stewart
TOP - January 2021 Vol 14, No 1
in
Hematologic Malignancies
Xevinapant plus CRT Improves Survival in Patients with Locally Advanced HNSCC
Patricia Stewart
TON - December 2020, Vol 13, No 6
in
Emerging Therapies
Sotorasib Demonstrates Promising Antitumor Activity in Patients with Advanced NSCLC
Patricia Stewart
TON - December 2020, Vol 13, No 6
in
Emerging Therapies
CAR T-Cell Therapy May Not Be Needed for Select Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Patricia Stewart
TON - December 2020, Vol 13, No 6
in
NCCN
Aggressive Approach to High-Risk Smoldering Myeloma Gains Consensus
Patricia Stewart
TON - December 2020, Vol 13, No 6
in
NCCN
Explosion of New Regimens for Multiple Myeloma: Selecting the Right Option for the Right Patient
Patricia Stewart
TON - December 2020, Vol 13, No 6
in
NCCN
Personalized Vaccine plus Atezolizumab Shows Promising Clinical Activity in Advanced Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
AACR Highlights
Olaparib Significantly Improves Survival in Men with Metastatic Prostate Cancer and BRCA Mutations
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
ESMO 2020
Surgery and Radiation Do Not Extend Survival in Newly Diagnosed Stage IV Breast Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
Breast Cancer
Relugolix May Become New Standard of Care for Advanced Prostate Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
Prostate Cancer
Immune Checkpoint Inhibitors Do Not Increase Mortality in Patients with Cancer and COVID-19
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
AACR Highlights
,
COVID-19
COVID-19 Increases Overall Risk for Death in Patients with Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
AACR Highlights
,
COVID-19
COVID-19: Facing the Challenges Ahead
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
AACR Highlights
,
COVID-19
Real-World Analysis Shows Survival Benefit with Adjuvant Immunotherapy in Stage III Melanoma
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
AACR Highlights
,
Melanoma
Cabozantinib plus Nivolumab Offers New First-Line Treatment Option for Patients with Advanced Renal-Cell Carcinoma
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
ESMO 2020
“Practice-Changing” Results Seen with Adjuvant Abemaciclib plus Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
Patricia Stewart
TOP - November 2020 Vol 13, No 6
in
ESMO 2020
Durvalumab plus Chemotherapy Improves Overall Survival in Extensive-Stage Small-Cell Lung Cancer
Patricia Stewart
TOP - September 2020 Vol 13, No 5
in
Lung Cancer
Adjuvant Atezolizumab Does Not Show Disease-Free Survival Benefit in High-Risk Bladder Cancer
Patricia Stewart
TOP - September 2020 Vol 13, No 5
in
Bladder Cancer
Avelumab as Maintenance Prolongs Survival in Advanced Bladder Cancer
Patricia Stewart
TOP - September 2020 Vol 13, No 5
in
Bladder Cancer
Last modified: August 17, 2020
Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
TOP
Print Edition
We will request your mailing address on the next page.
TOP
E-Newsletters and Communications
JHOP
Print Edition
We will request your mailing address on the next page.
JHOP
E-Newsletters and Communications
I have reviewed and consent to the terms of
TOP
's
Privacy Policy
, and
TOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
